$Greenidge Generation Holdings Inc.(GREE)$Correct me if i am wrong: Now conversion rate is changed to USD43.40, techincally the "mergered" investors need to be compensated for the price differences against their merger rates...Need professional advice on this[流泪] [流泪] [流泪] [流泪] [流泪]
$NRX Pharmaceuticals Inc.(NRXP)$https://lastfuturist.com/can-zyesami-treatment-reduce-mortality-rates-for-delta/?fbclid=IwAR3NpN3A5FQc2kJXx6AGPYe_eskJTn8K3c4jlTKUzjDfc4LKTjeHhUYhhvkIn the interview, Dr Javitt mentioned FDA wanted them to submit randomized controlled data, on top of their initial open-label data, and PR on Monday and the number we saw today was the randomized controlled data, and it seems very promising.The slide that Dr Javitt showed with heading of:“Zyesami demonstrates clear biologic effect in preventing IL-6 “Cytokine Storm” and then the chart showing Zyesami/Aviptadil treated patients were nearly 1,000% better off in IL-6 level than placebo patients really caught the attention of one of the other presenters who had been singing t
$NRX Pharmaceuticals Inc.(NRXP)$Good news.🤑🤑🤑NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory ConditionsWed, August 4, 2021, 6:48 PM·ZYESAMI™ (aviptadil) was awarded Fast Track Designation by the U.S. Food and Drug Administration for the Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome Associated with COVID-19- Potential Applications for Dry Powder Formulation of ZYESAMI™ Extend to Many Pulmonary Conditions Beyond COVID-19
$NRX Pharmaceuticals Inc.(NRXP)$As we wait patiently FDA approval. ⬇️"To our knowledge this is the first demonstration of clinically and statistically-significant benefit by any therapeutic agent in patients with COVID-19 respiratory failure in a randomized, double blind, prospective trial….. ZYESAMI, if authorized, would be the first drug for such critically ill patients. $nrxp